Navigation Links
Certain Diabetes Drugs May Pose Eye Risk
Date:4/7/2009

Use of Avandia, Actos tied to a retinal disorder, study finds

TUESDAY, April 7 (HealthDay News) -- A class of diabetes drugs called glitazones are associated with an increased risk of a vision-threatening complication called diabetic macular edema (DME), which features swelling and fluid accumulation in the retina.

Glitazones are a newer class of diabetes drugs that includes medicines such as pioglitazone (Actos) and rosiglitazone (Avandia).

The U.S. study of 996 DME patients found that those who took glitazones were 2.6 times more likely to develop DME than those who didn't take the drugs. Even after adjusting for other factors, the risk of DME remained 60 percent higher for patients who took glitazones, said the researchers at the Southern California Permanente Medical Group.

The study, published in the April issue of the American Journal of Ophthalmology, isn't the first to suggest a link between glitazones and DME. But it does confirm that the drugs are "modestly associated" with increased risk of DME, which is a common complication of diabetes.

"When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs," the study authors concluded.

"Ocular (eye) complications are an overlooked safety issue of systemic drugs," noted Dr. Thomas J. Liesegang, editor-in-chief of the American Journal of Ophthalmology.

"Safety is as important as the efficacy of a drug. However, long-term safety is not currently monitored, because the approval process is based on smaller, shorter-term clinical trials. Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time. This monitoring is often neglected and should be required of all therapies," Liesegang said.

More information

The American Diabetes Association has more about

Copyright©2009 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
3. MU researchers studying model to learn why certain cancers become resistant to drugs
4. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
5. Effectiveness of most PTSD therapies is uncertain
6. Value of Most Post-Traumatic Stress Treatments Uncertain
7. Certain Seizure Patients Need Emergency CT Scan
8. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
9. Certain Cholesterol Drugs Show Their Limits
10. ADHD Delays Growth of Certain Brain Areas
11. Stress hormone may hasten the progression of certain blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Diabetes Drugs May Pose Eye Risk
Certain Diabetes Drugs May Pose Eye Risk
(Date:2/9/2010)... Researchers at the Ireland Cancer Center of University Hospitals ... may lead to a new standard of care for ... in the February issue of Clinical Cancer Research, ... chemotherapy medicine, Triapine, was well tolerated in combination with ... cervical cancer. This regimen provided both significant reduction in ...
(Date:2/9/2010)... Act Could See Idaho Lose $1.6 Billion from ... , Feb. 9 As the Idaho ... non-existent federal health care law, the long-term effects of the ... calling the Idaho Health Freedom Act (House Bill 391) a ... law, could see Idaho lose nearly $1.6 ...
(Date:2/9/2010)... comprehensive study to date of secondhand smoke exposure among ... Addiction . The study, carried out by researchers ... that exposure to household secondhand smoke among children aged ... wanted to find out if there were ways to ... in private households, and whether those levels were changing ...
(Date:2/9/2010)... more soft drinks per week increased the risk of ... who did not consume soft drinks, according to a ... a journal of the American Association for Cancer Research. ... of the most deadly; only 5 percent of people ... Pereira, Ph.D., senior author on the study and associate ...
(Date:2/9/2010)... has increased in infants born prematurely in the US, ... Health System (LUHS). These findings were reported at the ... in Chicago. They also were published in the latest ... Gynecology . , Researchers reported that CP is associated ... cord. This inflammation is more common in premature births ...
Breaking Medicine News(10 mins):Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4Health News:Exposure to secondhand smoke among children in England has declined since 1996 2Health News:Soft drinks may increase risk of pancreatic cancer 2Health News:Incidence of cerebral palsy on rise in US 2
... 44 marked the peak of depression for people around ... People around the globe hit the height of their ... study suggests. , The finding by British and American ... approximately 2 million people in 80 nations. With few ...
... with prostate cancer who have their prostate removed ... effect after surgery, but urinary dysfunction troubles these ... Whats more, many arent emotionally prepared to face ... a recent issue of Urologic Nursing, underscore the ...
... MD, Elected 2008 President of the HBA, ... president at its,helm, Elizabeth M. Mutisya, MD, and ... Association (HBA) continues to,mark its 30th Anniversary with ... to furthering the advancement of women leaders in,healthcare ...
... Weston Medical Publishing is,pleased to announce that ... ), sister publication to the,well-known Journal of ... for,inclusion into the National Library of Medicine,s ... the PUBMED website or the MEDLARS system!, ...
... Action Healthcare to Offer Unique and Cost-Effective Approach to ... Patients ... 30 Life:WIRE(TM) Corp, a,dynamic mobile communications and health ... an agreement with Action,Healthcare Management, Inc. (AHM), a national ...
... Medical,Technologies, Inc. (Nasdaq: PMTI ), a leading researcher ... that it will,unveil two new fractional handpieces at the ... in San Antonio, Texas from February,2nd to 4th. Management ... to discuss Palomar,s full line of products in booth,#2121 ...
Other Medicine News:Health News:Middle Age a Low Point for Most 2Health News:Middle Age a Low Point for Most 3Health News:Urinary dysfunction troubles men who undergo prostate removal 2Health News:Urinary dysfunction troubles men who undergo prostate removal 3Health News:Healthcare Businesswomen's Association Announces 2008 Board of Directors 2Health News:Healthcare Businesswomen's Association Announces 2008 Board of Directors 3Health News:American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicine's MEDLINE Database and may now be Accessed Through the PUBMED Website or the MEDLARS System 2Health News:Life:WIRE(TM) to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 2Health News:Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting 2Health News:Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting 3Health News:Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting 4
(Date:2/9/2010)... Feb. 9 Delcath ... medical technology company testing its proprietary treatment system ... announced today the signing of its first research, ... Hepatic Perfusion (PHP) System  (the Delcath PHP System™). ... exclusive right to market and sell the Delcath ...
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/8/2010)... Calif. , Feb. 8 PreXion, ... quality 3D Cone Beam Imaging systems for dentistry, today ... as Director of Marketing. ,, PreXion President/COO ... Keith on our senior management team and I look ... extensive sales and marketing leadership, experience and success in ...
Breaking Medicine Technology:Delcath Signs First Partner Agreement in Asia 2Delcath Signs First Partner Agreement in Asia 3Delcath Signs First Partner Agreement in Asia 4Delcath Signs First Partner Agreement in Asia 5Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4PreXion, Inc. Announces Appointment of Director of Marketing 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 1BayCare Named CIO 100 Award Winner by CIO Magazine 47458 2BayCare Named CIO 100 Award Winner by CIO Magazine 47458 3NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 1FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 2FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 3FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 4FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 5FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 6FDA Approves Labeling Change for VYVANSE 28R 29 28lisdexamfetamine dimesylate 29 CII to Include Supplementary Clinical Data Supporting Efficacy at 13 12386 7
... - Research Collaboration to ... Jubilant Organosys Ltd, headquartered in ... Biosys Ltd, has signed a research,collaboration agreement with, ... the international pharmaceutical company,s pre-clinical,pipeline. Under the shared ...
... concludes that new cosmeceutical improves skin barrier function, erythema ... Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, today ... Lotion for Improving the Signs and Symptoms of Rosacea," ...
Other Medicine Technology:Jubilant Enters Research Collaboration With AstraZeneca 2Jubilant Enters Research Collaboration With AstraZeneca 3Jubilant Enters Research Collaboration With AstraZeneca 4Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
... many years experience in the field of Urodynamics, ... Urodynamics Chair. Our new chair is manufactured from ... of Urodynamic studies can be improved considerably if ... the test, and this aspect was given a ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... Osmometer provides extremely accurate osmolality measurements ... These results are obtained by using ... total concentration. Only the model 2020 ... sample handling, and flexible reporting options ...
Medicine Products: